CMPX vs. VERA, JANX, EVO, OCUL, MESO, TVTX, BGM, GPCR, CVAC, and CALT
Should you be buying Compass Therapeutics stock or one of its competitors? The main competitors of Compass Therapeutics include Vera Therapeutics (VERA), Janux Therapeutics (JANX), Evotec (EVO), Ocular Therapeutix (OCUL), Mesoblast (MESO), Travere Therapeutics (TVTX), BGM Group (BGM), Structure Therapeutics (GPCR), CureVac (CVAC), and Calliditas Therapeutics AB (publ) (CALT). These companies are all part of the "pharmaceutical products" industry.
Compass Therapeutics vs. Its Competitors
Compass Therapeutics (NASDAQ:CMPX) and Vera Therapeutics (NASDAQ:VERA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.
Vera Therapeutics' return on equity of -40.59% beat Compass Therapeutics' return on equity.
68.4% of Compass Therapeutics shares are held by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are held by institutional investors. 29.8% of Compass Therapeutics shares are held by company insiders. Comparatively, 16.3% of Vera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Compass Therapeutics has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500. Comparatively, Vera Therapeutics has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500.
Compass Therapeutics has higher revenue and earnings than Vera Therapeutics. Vera Therapeutics is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.
Compass Therapeutics presently has a consensus target price of $12.67, suggesting a potential upside of 383.46%. Vera Therapeutics has a consensus target price of $65.00, suggesting a potential upside of 174.84%. Given Compass Therapeutics' higher probable upside, equities analysts plainly believe Compass Therapeutics is more favorable than Vera Therapeutics.
In the previous week, Vera Therapeutics had 1 more articles in the media than Compass Therapeutics. MarketBeat recorded 5 mentions for Vera Therapeutics and 4 mentions for Compass Therapeutics. Vera Therapeutics' average media sentiment score of 1.49 beat Compass Therapeutics' score of 0.90 indicating that Vera Therapeutics is being referred to more favorably in the news media.
Summary
Compass Therapeutics beats Vera Therapeutics on 8 of the 14 factors compared between the two stocks.
Get Compass Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CMPX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CMPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Compass Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CMPX) was last updated on 7/2/2025 by MarketBeat.com Staff
Free CMPX Stock Alerts